Phase 1 trial will evaluate safety and immune response for a strain of Ebola virus disease with no licensed vaccines ...

Cambridge, Massachusetts-based Moderna, Inc. (MRNA) is a biotechnology company focused on developing medicines and vaccines ...

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results ...

Add Yahoo as a preferred source to see more of our stories on Google. Moderna said the FDA's refusal was inconsistent with previous feedback from the agency. - Graham Hughes/Bloomberg/Getty Images The ...

Biotechnology company Moderna (NASDAQ:MRNA) reported Q2 CY2026 results exceeding the market’s revenue expectations, with ...

Shares of the biotech Moderna were up on Wednesday, as the Trump administration’s shifting position on messenger RNA-based vaccines and therapeutics appeared to tilt slightly in the company’s favor.

Moderna, Inc. settles its LNP patent dispute with Arbutus and Genevant for a $950 million upfront payment, eliminating a major litigation overhang. MRNA secures royalty-free access to critical LNP ...

Five years ago, Moderna, Inc. (MRNA) and Novavax, Inc. (NVAX) were two of the most talked about stocks across platforms like Seeking Alpha, social media, and likely in the national press of most ...

A fresh era of earnings growth may be on the horizon.

Moderna’s shares rallied after the biotechnology company’s messenger RNA flu vaccine candidate showed positive results in a late-stage trial. In early trading, the shares were 4.3% higher at $28.34, ...

Moderna (MRNA +2.56%) pioneered the digital biotech framework using messenger RNA (mRNA) technology to create a new class of medicines. Based in Cambridge, Massachusetts, it operates on the principle ...